view more →
Aer Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class inhaled therapies that target mucus obstruction in chronic lung diseases.
view more →
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research.
view more →
AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics.
view more →
Atsena Therapeutics is a clinical-stage gene therapy company focused on reversing or preventing blindness from inherited retinal diseases
view more →
Axonis Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapies that target KCC2
view more →
Boston Immune Technologies & Therapeutics is a clinical-stage biotechnology company developing a novel class of antagonist antibodies
view more →
Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).
view more →
CREATE Medicines is a clinical-stage biotechnology company pioneering a new class of in vivo immune programming therapies
view more →
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. IPO in May 2017 (NASDAQ: GTHX) Acquired by Pharmacosmos in 2024
view more →
Graybug Vision, Inc. was a clinical-stage ophthalmology company developing sustained-release therapies. IPO in September 2020 (NASDAQ: GRAY).
view more →
MMvention Therapeutix, Inc. is an early-stage biotechnology company focused on discovering and developing novel oral small-molecule therapeutics
view more →
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company pioneering targeted protein degradation. IPO in August 2020 (NASDAQ: KYMR).
view more →
Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.
view more →
Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders.
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
view more →
Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies to improve retinal blood flow and treat ischemia-driven eye diseases.
view more →
Qpex Biopharma is a clinical-stage biopharmaceutical company developing novel anti-infective therapies. Acquired by Shionogi 2023
view more →
Ribometrix is a biotechnology company pioneering a new class of small-molecule therapeutics that directly target the three-dimensional structures of RNA to modulate disease biology.
view more →
Rodin Therapeutics was a biotechnology company focused on discovering and developing first-in-class small molecule therapeutics. Acquired by ALKS in Nov 2019
view more →
Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. IPO in October 2020 (NASDAQ: STTK)
view more →
Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023
view more →
Sensorium Therapeutics is a clinical-stage biotechnology company developing next-generation brain and mental health medicines.
view more →
Ten63 Therapeutics is a computational drug discovery company leveraging its proprietary AI- and physics-based platform to design novel therapeutics
view more →
Trefoil Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to restore vision for people with corneal diseases.
view more →
Tune Therapeutics is a biotechnology innovator advancing a new class of epi-therapeutic medicines
view more →
Viamet Pharmaceuticals is a biotechnology company. Acquired by NovaQuest Capital Management in January 2018.
view more →
Vigil Neuroscience is a clinical-stage biotechnology company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
